NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 36 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2020. The put-call ratio across all filers is 1.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27 | -3.6% | 300 | 0.0% | 0.00% | – |
| Q2 2023 | $28 | -99.9% | 300 | -99.8% | 0.00% | – |
| Q3 2022 | $48,000 | -70.7% | 190,752 | -16.1% | 0.00% | – |
| Q2 2022 | $164,000 | -5.7% | 227,452 | +3.3% | 0.00% | – |
| Q1 2022 | $174,000 | +10.8% | 220,100 | +39.8% | 0.00% | – |
| Q4 2021 | $157,000 | +823.5% | 157,400 | +1524.9% | 0.00% | – |
| Q3 2021 | $17,000 | +1600.0% | 9,687 | +1306.0% | 0.00% | – |
| Q2 2021 | $1,000 | -98.3% | 689 | -97.6% | 0.00% | – |
| Q1 2021 | $58,000 | +45.0% | 28,504 | +52.8% | 0.00% | – |
| Q4 2020 | $40,000 | -35.5% | 18,658 | -18.4% | 0.00% | – |
| Q3 2020 | $62,000 | -27.9% | 22,854 | +5.1% | 0.00% | – |
| Q2 2020 | $86,000 | +126.3% | 21,750 | -27.1% | 0.00% | – |
| Q4 2019 | $38,000 | +137.5% | 29,848 | +28.1% | 0.00% | – |
| Q3 2019 | $16,000 | +700.0% | 23,303 | +497.5% | 0.00% | – |
| Q2 2019 | $2,000 | – | 3,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Allred Capital Management, LLC | 36,838 | $26,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 102,440 | $74,000 | 0.00% |
| PDS Planning, Inc | 10,565 | $8,000 | 0.00% |
| UBS Group AG | 105 | $0 | 0.00% |
| Parallel Advisors, LLC | 350 | $0 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,722 | $1,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 4,954 | $3,000 | 0.00% |
| NORTHERN TRUST CORP | 39,414 | $28,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 227,452 | $164,000 | 0.00% |